This application seeks renewed CCSG funding for the City of Hope Comprehensive Cancer Center (COHCCC). The COHCCC brings together 131 Members from 34 Departments in the City of Hope Medical Center and the Beckman Research Institute. The Center receives $24,212,096M (Totals) from NCI, $25,947,483M from other peer-reviewed sources, and $31,421,929M from non-peer-reviewed sources, for a total of $81,581,508M in overall funding. Through faculty recruitment, reorganization, and significant infrastructure development, the COHCCC has greatly enhanced its ability to accelerate clinical and translational cancer-focused research. Seventy-two new faculty have been recruited, including 48 clinical investigators and 24 basic and population research scientists. The Cancer Center has five Programs: Molecular Oncology (MONC), Developmental Cancer Therapeutics (DCT), Cancer Immunotherapeutics (CI), Hematologic Malignancies (HM), and Cancer Control and Population Sciences (CCPS). Center membership has been honed to sharpen cancer focus and an Associate Member category has been created for investigators whose potential for peer-reviewed, cancer-focused research is yet developing. This application requests support for ten Shared Resources: Analytical Cytometry, Analytical Pharmacology, Bioinformatics, Functional Genomics/Genomic Sequencing, Pathology, Small Animal Imaging, Drug Discovery and Structural Biology, Survey Research, Biostatistics, and Clinical Protocol and Data Management. The COHCCC is primed to make significant advances in the coming years. Our 72 new basic, population and clinical research recruits will continue to introduce new ideas, technologies, and areas of research focus while enhancing the creative and innovative environment of the Center. Significant infrastructure and other resources have been created to facilitate the translation of discoveries to the rapid development of new cancer treatments, diagnostic tests, and other interventions that would aid people with cancer, as well as individuals at risk for malignancy. Finally, the overall configuration of the institution and its administrative capabilities in terms f leadership, programmatic alignment, development, and authority that have been augmented so that the Cancer Center will be more responsive to its members and to harness their collective energies and creativity. This proposal documents that the COHCCC has built a solid structure for achieving its missions and is stronger and more sustainable than it has ever been.
; Organizational capabilities under the authority of the Cancer Center Director are key for appropriate leadership, evaluation and planning. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.
|Chen, Robert W; Palmer, Joycelynne M; Tomassetti, Sarah et al. (2018) Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol 11:87|
|Romsdahl, Jillian; Blachowicz, Adriana; Chiang, Abby J et al. (2018) Characterization of Aspergillus niger Isolated from the International Space Station. mSystems 3:|
|Gong, Jun; Salgia, Ravi (2018) Managing Patients With Relapsed Small-Cell Lung Cancer. J Oncol Pract 14:359-366|
|Lueschow, Shiloh R; Stumphy, Jessica; Gong, Huiyu et al. (2018) Loss of murine Paneth cell function alters the immature intestinal microbiome and mimics changes seen in neonatal necrotizing enterocolitis. PLoS One 13:e0204967|
|Gu, Long; Lingeman, Robert; Yakushijin, Fumiko et al. (2018) The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA. Clin Cancer Res 24:6053-6065|
|Sen, Subha; He, Zhiheng; Ghosh, Shubhamoy et al. (2018) PRMT1 Plays a Critical Role in Th17 Differentiation by Regulating Reciprocal Recruitment of STAT3 and STAT5. J Immunol 201:440-450|
|Weitzel, Jeffrey N; Chao, Elizabeth C; Nehoray, Bita et al. (2018) Somatic TP53 variants frequently confound germ-line testing results. Genet Med 20:809-816|
|Ghose, Jayeeta; Viola, Domenico; Terrazas, Cesar et al. (2018) Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology 7:e1486948|
|Aslamy, Arianne; Oh, Eunjin; Olson, Erika M et al. (2018) Doc2b Protects ?-Cells Against Inflammatory Damage and Enhances Function. Diabetes 67:1332-1344|
|Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707|
Showing the most recent 10 out of 1396 publications